Diridavumab

Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]

Diridavumab
Monoclonal antibody
Type	?
Source	Human
Target	hemagglutinin
Clinical data
Other names	CR6261
ATC code	none
Identifiers
CAS Number	1393659-46-5
ChemSpider	none
UNII	JFC86A9HL9
Chemical and physical data
Formula	C₆₄₀₀H₉₉₃₄N₁₇₀₂O₁₉₉₆S₄₈
Molar mass	144196.67 g·mol⁻¹

This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.

References

World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Bamlanivimab^† Casirivimab^† (+imdevimab)^† Diridavumab^§ Exbivirumab^§ Foravirumab^§ Imdevimab^† Libivirumab^§ Maftivimab Odesivimab Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.